Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine is a clinical-stage biopharmaceutical company with a diverse pipeline focused on the development and commercialization of novel treatments for hematologic diseases. Its upcoming pivotal data readouts for bitopertin in erythropoietic porphyrias and DISC-0974 in anemia of myelofibrosis have the potential to de-risk and drive significant value for the company. Additionally, the recent FDA alignment and clarity on regulatory requirements provide a positive outlook for future success.

Bears say

Disc Medicine is a clinical-stage biopharmaceutical company with a negative outlook due to significant risks to the advancement of its main pipeline candidates, bitopertin, DISC-0974, and DISC-3405, in the clinic. Potential failures in clinical trials or unexpected toxicities could harm the company's ability to develop these treatments for anemia and other hematologic disorders, undermining its potential for commercial success. Furthermore, the company's heavy focus on rare diseases may limit its potential for market penetration and commercial viability.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.